AllianceBernstein’s Indivior Pharmaceuticals INDV Stock Holding History

AllianceBernstein’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.9M	Buy	160,600 +19,000	+13%	+$689K	﹤0.01%	1556
2026 Q1	$4.32M	Buy	141,600 +1,400	+1%	+$46.2K	﹤0.01%	1606
2025 Q4	$5.03M	Buy	140,200 +11,900	+9%	+$363K	﹤0.01%	1539
2025 Q3	$3.09M	Sell	128,300 -8,234	-6%	-$172K	﹤0.01%	1762
2025 Q2	$2.01M	Buy	136,534 +123,500	+948%	+$1.44M	﹤0.01%	1927
2025 Q1	$124K	Hold	13,034	–	–	﹤0.01%	3032
2024 Q4	$162K	Hold	13,034	–	–	﹤0.01%	3065
2024 Q3	$127K	Hold	13,034	–	–	﹤0.01%	3103
2024 Q2	$210K	Hold	13,034	–	–	﹤0.01%	3016
2024 Q1	$279K	Hold	13,034	–	–	﹤0.01%	2826
2023 Q4	$199K	Hold	13,034	–	–	﹤0.01%	2979
2023 Q3	$301K	Hold	13,034	–	–	﹤0.01%	2807
2023 Q2	$310K	Buy	+13,034	New	+$299K	﹤0.01%	2845

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein's INDV Position: Q2 2026 in Review

AllianceBernstein increased its Indivior Pharmaceuticals (INDV) stake by 13% in Q2 2026, buying an estimated $689K and bringing the position to 160,600 shares worth $4.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

AllianceBernstein first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.03M in Q4 2025. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

AllianceBernstein held 160,600 shares of Indivior Pharmaceuticals worth $4.9M as of Q2 2026.
AllianceBernstein bought 19,000 Indivior Pharmaceuticals shares in Q2 2026, an estimated $689K.
Indivior Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1556 holding.
AllianceBernstein first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
AllianceBernstein's Indivior Pharmaceuticals position peaked at $5.03M in Q4 2025.
339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.